Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 02, 2023 | May 04, 2023 |
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | Director · Chairman, President & CEO | August 03, 2026 | August 05, 2026 |
| CVS HEALTH CorpCVS · Entity 2884 | Director | May 14, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date May 02, 2023 · Filed May 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 9,692 |
Reported balance
After 2023-05-02 transaction · row 1
1 source rowRow 1 · 2023-05-02 · Grant · Acquired 4,573 · Balance 9,692 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. |
| Common Stock, $1 par valueSEC Table I · non-derivative | IndirectShares owned by Michael F. Mahoney Revocable Trust | 20,397 |
Reported balance
Holding disclosure · report date 2023-05-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,397 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
BOSTON SCIENTIFIC CORP
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,590,024 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Purchase · Acquired 186,240 · Balance 1,590,024 F1: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 22,119 |
Reported balance
After 2026-08-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-03 · Other · Acquired 22,119 · Balance 22,119 F2: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
CVS HEALTH Corp
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,428.8174 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 1,737.0046 · Balance 6,428.8174 F1: Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. F2: Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.
F2: Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 18,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · derivative · entry 12 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,334 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 8,865 | $106.11 | $940,665.15 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,653,354 Read SEC document |
| February 17, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 18,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 5 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,662,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 16,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · derivative · entry 11 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,265 Underlying: Common Stock · 16,265 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,865 | $106.11 | $834,555.15 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,643,885 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,651,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 16,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · derivative · entry 10 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,048 Underlying: Common Stock · 16,524 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,990 | $106.11 | $847,818.90 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,635,485 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,643,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 90,915 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · derivative · entry 9 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,915 Underlying: Common Stock · 90,915 shares Expires 2035-02-13 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 35,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · derivative · entry 8 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,330 Underlying: Common Stock · 35,330 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 13,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001792 · doc4.xml · derivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,112 Underlying: Common Stock · 13,704 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 6,626 | $105.77 | $700,832.02 |
DisclosureSEC source: 0001225208-25-001792 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,626,951 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 13,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001792 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,633,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 62,915 | $105.98 | $6,667,731.70 |
DisclosureSEC source: 0001225208-25-001684 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,619,873 Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 130,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001684 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,682,788 F1 · kind: On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 57,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-000205 · doc4.xml · derivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,121 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 25,656 | $89.32 | $2,291,593.92 |
DisclosureSEC source: 0001225208-25-000205 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,552,670 Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 57,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-000205 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,578,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-010259 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 201,478 Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 2,200 | $57.10 | $125,620.00 |
DisclosureSEC source: 0001127602-24-028001 · form4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,201 F1 · shares: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 55,676 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-24-009728 · doc4.xml · derivative · entry 7 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,676 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,211 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-24-009728 · doc4.xml · derivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,635 Underlying: Common Stock · 56,211 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 160,182 | $84.74 | $13,573,742.59 |
DisclosureSEC source: 0001225208-24-009728 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,521,205 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.145 to $85.12, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,596 | $85.17 | $221,108.33 |
DisclosureSEC source: 0001225208-24-009728 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,681,387 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.14 to $85.20, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 55,676 | $16.31 | $908,075.56 |
DisclosureSEC source: 0001225208-24-009728 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,683,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 56,211 | $17.26 | $970,201.86 |
DisclosureSEC source: 0001225208-24-009728 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,628,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 55,675 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-24-009234 · doc4.xml · derivative · entry 7 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,676 Underlying: Common Stock · 55,675 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,211 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-24-009234 · doc4.xml · derivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224,846 Underlying: Common Stock · 56,211 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 82,085 | $84.94 | $6,972,431.24 |
DisclosureSEC source: 0001225208-24-009234 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,572,096 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.75 to $85.24, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 80,692 | $84.31 | $6,803,360.39 |
DisclosureSEC source: 0001225208-24-009234 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,654,181 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.73, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 55,675 | $16.31 | $908,059.25 |
DisclosureSEC source: 0001225208-24-009234 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,734,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 56,211 | $17.26 | $970,201.86 |
DisclosureSEC source: 0001225208-24-009234 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,679,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 55,675 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-24-008529 · doc4.xml · derivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,351 Underlying: Common Stock · 55,675 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,211 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-24-008529 · doc4.xml · derivative · entry 5 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,057 Underlying: Common Stock · 56,211 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 162,777 | $81.17 | $13,212,543.98 |
DisclosureSEC source: 0001225208-24-008529 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,622,987 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $80.52 to $81.80, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 55,675 | $16.31 | $908,059.25 |
DisclosureSEC source: 0001225208-24-008529 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,785,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 56,211 | $17.26 | $970,201.86 |
DisclosureSEC source: 0001225208-24-008529 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,730,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. Read SEC document |
| August 30, 2024 Filed Sep 3, 2024 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 176,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-008332 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 209,278 F3 · kind: This transaction involved a gift of securities by the reporting person to The Michael F. Mahoney 2 Year Qualified Annuity Trust - 2024, which is administered by an independent trustee. Read SEC document |
| August 30, 2024 Filed Sep 3, 2024 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 95,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-008332 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 385,523 F2 · kind: This transaction involved a gift of securities by The Michael F. Mahoney 2 Year Qualified Annuity Trust - 2022, which is administered by an independent trustee. Read SEC document |
| August 30, 2024 Filed Sep 3, 2024 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 114,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-008332 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 290,482 F1 · kind: This transaction involved a gift of securities by The Michael F. Mahoney 2 Year Qualified Annuity Trust - 2023, which is administered by an independent trustee. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:40 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 2,184 | $57.52 | $125,623.68 |
DisclosureSEC source: 0001127602-24-015902 · form4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,001 F1 · kind: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan. Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:30 UTC | CVS HEALTH Corp CVS · Entity 2884 | PurchaseCommon Stock (By Trust) | 9,181 | $54.49 | $500,293.81 |
DisclosureSEC source: 0001127602-24-013995 · form4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,356 F1 · security: Consists of shares held in trusts for the benefit of the reporting person or the reporting person and his spouse. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 16,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002576 · doc4.xml · derivative · entry 10 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,307 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,233 | $65.82 | $476,076.06 |
DisclosureSEC source: 0001225208-24-002576 · doc4.xml · nonDerivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,673,878 Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002576 · doc4.xml · nonDerivative · entry 5 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,681,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. Read SEC document |
| February 17, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002576 · doc4.xml · derivative · entry 9 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,334 Underlying: Common Stock · 18,333 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 8,131 | $65.82 | $535,182.42 |
DisclosureSEC source: 0001225208-24-002576 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,664,804 Read SEC document |
| February 17, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002576 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,672,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 16,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002576 · doc4.xml · derivative · entry 8 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,530 Underlying: Common Stock · 16,265 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.